Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil and Propecia are the only FDA-approved hair growth drugs, but concerns about side effects lead people to explore herbal alternatives.

Direct-to-consumer teledermatology platforms have financial conflicts of interest and lack proper patient care and follow-up.

Dermatologists can use social media to better educate people about hair loss treatments.

Low-dose oral minoxidil may be a promising alternative to topical minoxidil for hair loss.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

Lasers are FDA-approved for permanent hair reduction, not removal, and more research is needed to improve treatments.

Many treatments for hair loss lack proper testing and FDA approval, so their effectiveness is uncertain.

The FDA rejected a testosterone drug again due to safety concerns.

PRP therapy may effectively treat hair loss, but more research needed.

Neuroactive steroids show promise for treating mental and neurological disorders by targeting GABA_A receptors.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Low-Level Laser Therapy helps heal wounds and regenerate tissue when used correctly.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Different drug doses approved in Japan and the U.S. are not mainly due to different clinical responses, and ethnic factors should be considered in setting drug doses.

Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Finasteride has a higher risk of reproductive side effects than minoxidil.

Scalp cooling is the most effective FDA-approved method to prevent chemotherapy-induced hair loss, but more research is needed for other treatments.

The document concludes that proper diagnosis and FDA-approved treatments for different types of hair loss exist, but treatments for severe cases often fail and future improvements may focus on hair follicle stem cells.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Hormonal therapies like cyproterone acetate and spironolactone may help some women with hair loss, but finasteride 1mg is not useful, and the effectiveness of other treatments is still unclear.

The document suggests a need for collaboration, better evidence, and a responsible framework to safely and effectively advance regenerative therapies to clinical use.

The document concludes that mesotherapy can be effective for skin and hair treatments, but more research is needed to confirm its safety and effectiveness.

Certain drugs are effective for skin conditions like psoriasis, vitiligo, and hair loss.

Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.

Hormonal therapy like cyproterone acetate and spironolactone may help female hair loss, but more research is needed, especially for pre-menopausal women.

Cancer treatments often cause hair loss, and more research is needed to prevent and treat it.

Choose between topical and oral minoxidil for hair growth based on personal tolerance and side effects.